NO20031525L - Kjemokinmutanter i behandlingen av multippel sklerose - Google Patents

Kjemokinmutanter i behandlingen av multippel sklerose

Info

Publication number
NO20031525L
NO20031525L NO20031525A NO20031525A NO20031525L NO 20031525 L NO20031525 L NO 20031525L NO 20031525 A NO20031525 A NO 20031525A NO 20031525 A NO20031525 A NO 20031525A NO 20031525 L NO20031525 L NO 20031525L
Authority
NO
Norway
Prior art keywords
treatment
multiple sclerosis
chemokine mutants
chemokine
mutants
Prior art date
Application number
NO20031525A
Other languages
English (en)
Other versions
NO20031525D0 (no
NO330278B1 (no
Inventor
Amanda Proudfoot
Timothy N C Wells
Marie Kosco-Vilbois
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20031525L publication Critical patent/NO20031525L/no
Publication of NO20031525D0 publication Critical patent/NO20031525D0/no
Publication of NO330278B1 publication Critical patent/NO330278B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20031525A 2000-10-04 2003-04-03 Anvendelse av en CC-kjemokinmutant i fremstillingen av en farmasoytisk sammensetning til behandlingen av multippel sklerose og/eller andre demyelinerende sykdommer, farmasoytisk sammensetning omfattende mutantene, trunkert og mutert human RANTES og rekombinant fremgangsmate for fremstilling av samme,DNA-molekyl som koder for dette, ekspresjonsvektor som omfatter DNA-molekylet og vertscelle som omfatter ekspresjonsvektoren NO330278B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00121665 2000-10-04
PCT/EP2001/011428 WO2002028419A2 (en) 2000-10-04 2001-10-03 Chemokine mutants in the treatment of multiple sclerosis

Publications (3)

Publication Number Publication Date
NO20031525L true NO20031525L (no) 2003-04-03
NO20031525D0 NO20031525D0 (no) 2003-04-03
NO330278B1 NO330278B1 (no) 2011-03-21

Family

ID=8170011

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031525A NO330278B1 (no) 2000-10-04 2003-04-03 Anvendelse av en CC-kjemokinmutant i fremstillingen av en farmasoytisk sammensetning til behandlingen av multippel sklerose og/eller andre demyelinerende sykdommer, farmasoytisk sammensetning omfattende mutantene, trunkert og mutert human RANTES og rekombinant fremgangsmate for fremstilling av samme,DNA-molekyl som koder for dette, ekspresjonsvektor som omfatter DNA-molekylet og vertscelle som omfatter ekspresjonsvektoren

Country Status (30)

Country Link
US (1) US7402303B2 (no)
EP (1) EP1326628B1 (no)
JP (1) JP3908165B2 (no)
KR (1) KR100837898B1 (no)
CN (1) CN1285381C (no)
AR (1) AR030854A1 (no)
AT (1) ATE265222T1 (no)
AU (2) AU2002215919B2 (no)
BG (1) BG66137B1 (no)
BR (1) BR0114407A (no)
CA (1) CA2423616C (no)
CZ (1) CZ303409B6 (no)
DE (1) DE60103078T2 (no)
DK (1) DK1326628T3 (no)
EA (1) EA006137B1 (no)
EE (1) EE05174B1 (no)
ES (1) ES2217199T3 (no)
HR (1) HRP20030215B1 (no)
HU (1) HUP0302194A3 (no)
IL (2) IL155178A0 (no)
MX (1) MXPA03003008A (no)
NO (1) NO330278B1 (no)
PL (1) PL204231B1 (no)
PT (1) PT1326628E (no)
RS (1) RS50738B (no)
SI (1) SI1326628T1 (no)
SK (1) SK287523B6 (no)
UA (1) UA77950C2 (no)
WO (1) WO2002028419A2 (no)
ZA (1) ZA200302315B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2468790A1 (en) 2001-12-17 2003-06-26 Applied Research Systems Ars Holding N.V. Chemokine mutants acting as chemokine antagonists
AU2003240758B2 (en) 2002-04-04 2008-03-13 Laboratoires Serono Sa Chemokines mutants having improved oral bioavailability
DE60320848D1 (de) * 2002-12-23 2008-06-19 Serono Lab Verwendung von cc-chemokine ccl5/rantes mutanten zur behandlung von lebererkrankungen
US20090022657A1 (en) * 2003-10-22 2009-01-22 Applied Research Systems Ars Holding N.V. Novel CXCL8 antagonists
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
PT1439191E (pt) * 2004-01-19 2006-06-30 Ares Trading Sa Processo para a purificacao de proteinas expressas de forma bacteriana
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
EP1760110B1 (en) * 2005-09-03 2011-11-02 Samsung SDI Co., Ltd. Polybenzoxazine-based compound, electrolyte membrane including the same, and fuel cell employing the electrolyte membrane
GB0614755D0 (en) 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
WO2009054873A2 (en) 2007-08-02 2009-04-30 Novimmune S.A. Anti-rantes antibodies and methods of use thereof
CA2788902C (en) * 2010-02-08 2019-09-03 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
CN112469430B (zh) 2018-05-28 2024-12-24 日内瓦大学 抑制大脑炎症的方法
WO2022093857A1 (en) * 2020-10-26 2022-05-05 City Of Hope Oncolytic virus compositions and methods for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1998006751A1 (en) * 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists
EP0906954A1 (en) * 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
ATE308617T1 (de) 1997-12-23 2005-11-15 San Raffaele Centro Fond Rantes mutanten und deren therapeutischen anwendungen
CA2361256A1 (en) * 1999-01-29 2000-08-03 James B. Rottman Method of treating demyelinating inflammatory disease using ccr1 antagonists

Also Published As

Publication number Publication date
HRP20030215A2 (en) 2005-02-28
IL155178A (en) 2009-07-20
JP2004510426A (ja) 2004-04-08
HUP0302194A2 (hu) 2003-10-28
WO2002028419A3 (en) 2002-06-13
CN1477969A (zh) 2004-02-25
HRP20030215B1 (en) 2011-09-30
US7402303B2 (en) 2008-07-22
DE60103078D1 (de) 2004-06-03
SK4062003A3 (en) 2003-08-05
SI1326628T1 (en) 2004-10-31
IL155178A0 (en) 2003-11-23
CZ2003947A3 (cs) 2003-11-12
CN1285381C (zh) 2006-11-22
ATE265222T1 (de) 2004-05-15
RS50738B (sr) 2010-08-31
SK287523B6 (sk) 2011-01-04
BG107685A (bg) 2003-11-28
HK1062811A1 (en) 2004-11-26
PL362350A1 (en) 2004-10-18
DE60103078T2 (de) 2005-04-07
EE200300139A (et) 2003-06-16
ZA200302315B (en) 2004-03-25
CA2423616A1 (en) 2002-04-11
WO2002028419A2 (en) 2002-04-11
ES2217199T3 (es) 2004-11-01
NO20031525D0 (no) 2003-04-03
DK1326628T3 (da) 2004-08-09
EA006137B1 (ru) 2005-10-27
BG66137B1 (bg) 2011-07-29
AU2002215919B2 (en) 2005-11-24
AU1591902A (en) 2002-04-15
AR030854A1 (es) 2003-09-03
CA2423616C (en) 2010-03-16
JP3908165B2 (ja) 2007-04-25
CZ303409B6 (cs) 2012-09-05
EP1326628A2 (en) 2003-07-16
EA200300439A1 (ru) 2003-08-28
HUP0302194A3 (en) 2005-12-28
KR100837898B1 (ko) 2008-06-13
KR20030034238A (ko) 2003-05-01
EE05174B1 (et) 2009-06-15
BR0114407A (pt) 2003-07-29
MXPA03003008A (es) 2003-07-14
US20040101509A1 (en) 2004-05-27
EP1326628B1 (en) 2004-04-28
UA77950C2 (en) 2007-02-15
PL204231B1 (pl) 2009-12-31
YU25703A (sh) 2006-05-25
NO330278B1 (no) 2011-03-21
PT1326628E (pt) 2004-09-30

Similar Documents

Publication Publication Date Title
IL155092A0 (en) Compounds useful in the treatment of inflammatory diseases
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
IL142908A0 (en) Compounds useful in the treatment of inflammatory diseases
FR2804864B1 (fr) Extraits de residus issus de la fabrication du vin et leur utilisation en cosmetique ou pharmacologie
EE200200286A (et) Uued aminopropüülfosfiinhapped ning nende kasutamine
ID28997A (id) Kedok sekali pakai, dan proses pembuatannya
PL366305A1 (en) Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors
NO20006113L (no) Anvendelse av cyklosporiner i behandlingen av inflammatoriske autoimmune sykdommer
AU2001234837A1 (en) Azapeptides useful in the treatment of hepatitis c
EE04490B1 (et) Ühend, selle valmistamise meetod ning kasutamine meditsiinis
NO20031525L (no) Kjemokinmutanter i behandlingen av multippel sklerose
CA96874S (en) Set of flatware
AU2001265186A1 (en) Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
NO20025964D0 (no) Ny interferon for behandling av multippel sklerose
CA96875S (en) Set of flatware
HUP0400262A3 (en) Glycopeptides, their preparation and use in the treatment of multiple sclerosis
GB0007217D0 (en) Materials and methods relating to the treatment of leukaemias
GB0114231D0 (en) Treatment of multiple sclerosis
AU5565401A (en) Materials and methods for the treatment of depression
IL162507A (en) Use of ifnar2 mutants in the manufacture of medicaments
NO962503D0 (no) Anvendelse av penoksyfyllin ved behandling av multippel sklerose
EE200300013A (et) Bispidiini uued ühendid ning nende kasutamine südame arütmia ravis
CA96876S (en) Set of flatware
NO20030762L (no) Forbedret spesifisitet i behandling av sykdommer
IT1316386B1 (it) Metodo per la fabbricazione di mobili in particolare piccoli mobili da bagno e mobili ottenuti.

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

MM1K Lapsed by not paying the annual fees